Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza

 Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza

Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza

Shots:

  • The P-III BLOCKSTONE study results involves assessing of Xofluza vs PBO in children & adults diagnosed with influenza, confirmed by rapid influenza diagnostic test in Japan
  • The P-III BLOCKSTONE study results: household members infected with flu (1.9% vs 13.6%); well tolerated; no new signals are observed; conducted by Shionogi
  • Xofluza is oral therapy to treat influenza in both healthy people with flu & at high risk of flu, evaluated in CAPSTONE-1 & 2 study respectively and is approved in Japan & US with its expected FDA’s approval for the treatment of flu in patients with asthma, chronic lung disease, morbid obesity and heart disease by Nov 04, 2019

Click here to read full press release/ article | Ref: Roche | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post